Additional cellular markers of MM that allow us to account more accurately for the disease heterogeneity, such as CD46 or BCMA, should be considered when studying MM, of which next-generation flow and mass cytometry that allow for a greater number of cellular markers will be instrumental. This evidence concerns the gene CD46 and Miyoshi myopathy.